These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 35654352)
1. Alterations of bone material properties in growing Ifitm5/BRIL p.S42 knock-in mice, a new model for atypical type VI osteogenesis imperfecta. Hedjazi G; Guterman-Ram G; Blouin S; Schemenz V; Wagermaier W; Fratzl P; Hartmann MA; Zwerina J; Fratzl-Zelman N; Marini JC Bone; 2022 Sep; 162():116451. PubMed ID: 35654352 [TBL] [Abstract][Full Text] [Related]
2. Hypermineralization and High Osteocyte Lacunar Density in Osteogenesis Imperfecta Type V Bone Indicate Exuberant Primary Bone Formation. Blouin S; Fratzl-Zelman N; Glorieux FH; Roschger P; Klaushofer K; Marini JC; Rauch F J Bone Miner Res; 2017 Sep; 32(9):1884-1892. PubMed ID: 28548288 [TBL] [Abstract][Full Text] [Related]
3. A novel IFITM5 mutation in severe atypical osteogenesis imperfecta type VI impairs osteoblast production of pigment epithelium-derived factor. Farber CR; Reich A; Barnes AM; Becerra P; Rauch F; Cabral WA; Bae A; Quinlan A; Glorieux FH; Clemens TL; Marini JC J Bone Miner Res; 2014 Jun; 29(6):1402-11. PubMed ID: 24519609 [TBL] [Abstract][Full Text] [Related]
4. Unique micro- and nano-scale mineralization pattern of human osteogenesis imperfecta type VI bone. Fratzl-Zelman N; Schmidt I; Roschger P; Roschger A; Glorieux FH; Klaushofer K; Wagermaier W; Rauch F; Fratzl P Bone; 2015 Apr; 73():233-41. PubMed ID: 25554599 [TBL] [Abstract][Full Text] [Related]
5. Type V OI primary osteoblasts display increased mineralization despite decreased COL1A1 expression. Reich A; Bae AS; Barnes AM; Cabral WA; Hinek A; Stimec J; Hill SC; Chitayat D; Marini JC J Clin Endocrinol Metab; 2015 Feb; 100(2):E325-32. PubMed ID: 25387264 [TBL] [Abstract][Full Text] [Related]
6. Crispr-Cas9 engineered osteogenesis imperfecta type V leads to severe skeletal deformities and perinatal lethality in mice. Rauch F; Geng Y; Lamplugh L; Hekmatnejad B; Gaumond MH; Penney J; Yamanaka Y; Moffatt P Bone; 2018 Feb; 107():131-142. PubMed ID: 29174564 [TBL] [Abstract][Full Text] [Related]
7. CRTAP deficiency leads to abnormally high bone matrix mineralization in a murine model and in children with osteogenesis imperfecta type VII. Fratzl-Zelman N; Morello R; Lee B; Rauch F; Glorieux FH; Misof BM; Klaushofer K; Roschger P Bone; 2010 Mar; 46(3):820-6. PubMed ID: 19895918 [TBL] [Abstract][Full Text] [Related]
8. The osteogenic cell surface marker BRIL/IFITM5 is dispensable for bone development and homeostasis in mice. Patoine A; Husseini A; Kasaai B; Gaumond MH; Moffatt P PLoS One; 2017; 12(9):e0184568. PubMed ID: 28880886 [TBL] [Abstract][Full Text] [Related]
9. Topological mapping of BRIL reveals a type II orientation and effects of osteogenesis imperfecta mutations on its cellular destination. Patoine A; Gaumond MH; Jaiswal PK; Fassier F; Rauch F; Moffatt P J Bone Miner Res; 2014 Sep; 29(9):2004-16. PubMed ID: 24715519 [TBL] [Abstract][Full Text] [Related]
10. A transgenic mouse model of OI type V supports a neomorphic mechanism of the IFITM5 mutation. Lietman CD; Marom R; Munivez E; Bertin TK; Jiang MM; Chen Y; Dawson B; Weis MA; Eyre D; Lee B J Bone Miner Res; 2015 Mar; 30(3):489-98. PubMed ID: 25251575 [TBL] [Abstract][Full Text] [Related]
11. Osteogenesis Imperfecta: Mechanisms and Signaling Pathways Connecting Classical and Rare OI Types. Jovanovic M; Guterman-Ram G; Marini JC Endocr Rev; 2022 Jan; 43(1):61-90. PubMed ID: 34007986 [TBL] [Abstract][Full Text] [Related]
12. IFITM5 mutations and osteogenesis imperfecta. Hanagata N J Bone Miner Metab; 2016 Mar; 34(2):123-31. PubMed ID: 26031935 [TBL] [Abstract][Full Text] [Related]
13. Mineral particle size in children with osteogenesis imperfecta type I is not increased independently of specific collagen mutations. Fratzl-Zelman N; Schmidt I; Roschger P; Glorieux FH; Klaushofer K; Fratzl P; Rauch F; Wagermaier W Bone; 2014 Mar; 60():122-8. PubMed ID: 24296239 [TBL] [Abstract][Full Text] [Related]
14. The Osteogenesis Imperfecta Type V Mutant BRIL/IFITM5 Promotes Transcriptional Activation of MEF2, NFATc, and NR4A in Osteoblasts. Maranda V; Gaumond MH; Moffatt P Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216266 [TBL] [Abstract][Full Text] [Related]
15. Severely Impaired Bone Material Quality in Chihuahua Zebrafish Resembles Classical Dominant Human Osteogenesis Imperfecta. Fiedler IAK; Schmidt FN; Wölfel EM; Plumeyer C; Milovanovic P; Gioia R; Tonelli F; Bale HA; Jähn K; Besio R; Forlino A; Busse B J Bone Miner Res; 2018 Aug; 33(8):1489-1499. PubMed ID: 29665086 [TBL] [Abstract][Full Text] [Related]
16. Two mutations in IFITM5 causing distinct forms of osteogenesis imperfecta. Guillén-Navarro E; Ballesta-Martínez MJ; Valencia M; Bueno AM; Martinez-Glez V; López-González V; Burnyte B; Utkus A; Lapunzina P; Ruiz-Perez VL Am J Med Genet A; 2014 May; 164A(5):1136-42. PubMed ID: 24478195 [TBL] [Abstract][Full Text] [Related]
17. Altered lacunar and vascular porosity in osteogenesis imperfecta mouse bone as revealed by synchrotron tomography contributes to bone fragility. Carriero A; Doube M; Vogt M; Busse B; Zustin J; Levchuk A; Schneider P; Müller R; Shefelbine SJ Bone; 2014 Apr; 61():116-24. PubMed ID: 24373921 [TBL] [Abstract][Full Text] [Related]
18. Col1A-2 Mutation in Osteogenesis Imperfecta Mice Contributes to Long Bone Fragility by Modifying Cell-Matrix Organization. André G; Chretien A; Demoulin A; Beersaerts M; Docquier PL; Behets C Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069332 [TBL] [Abstract][Full Text] [Related]
19. Bone mineral properties in growing Col1a2(+/G610C) mice, an animal model of osteogenesis imperfecta. Masci M; Wang M; Imbert L; Barnes AM; Spevak L; Lukashova L; Huang Y; Ma Y; Marini JC; Jacobsen CM; Warman ML; Boskey AL Bone; 2016 Jun; 87():120-9. PubMed ID: 27083399 [TBL] [Abstract][Full Text] [Related]
20. Increased Osteocyte Lacunae Density in the Hypermineralized Bone Matrix of Children with Osteogenesis Imperfecta Type I. Mähr M; Blouin S; Behanova M; Misof BM; Glorieux FH; Zwerina J; Rauch F; Hartmann MA; Fratzl-Zelman N Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925942 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]